Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

Similar articles for PubMed (Select 18381901)

1.

Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.

Gründer G, Fellows C, Janouschek H, Veselinovic T, Boy C, Bröcheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rösch F, Schaefer WM, Vernaleken I.

Am J Psychiatry. 2008 Aug;165(8):988-95. doi: 10.1176/appi.ajp.2008.07101574. Epub 2008 Apr 1.

PMID:
18381901
2.

Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.

Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A.

Neuropsychopharmacology. 2008 Dec;33(13):3111-25. doi: 10.1038/npp.2008.33. Epub 2008 Apr 16.

3.

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).

Vernaleken I, Fellows C, Janouschek H, Bröcheler A, Veselinovic T, Landvogt C, Boy C, Buchholz HG, Spreckelmeyer K, Bartenstein P, Cumming P, Hiemke C, Rösch F, Schäfer W, Wong DF, Gründer G.

J Clin Psychopharmacol. 2008 Dec;28(6):608-17. doi: 10.1097/JCP.0b013e31818ba2f6.

PMID:
19011428
4.

Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.

Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S.

Am J Psychiatry. 2007 Sep;164(9):1411-7.

PMID:
17728427
5.

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.

Gründer G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T, Härtter S, Schreckenberger M, Stoeter P, Hiemke C, Rösch F, Wong DF, Bartenstein P.

Neuropsychopharmacology. 2006 May;31(5):1027-35.

6.

A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.

Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G.

Am J Psychiatry. 2004 May;161(5):818-25.

PMID:
15121646
7.

Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.

Vernaleken I, Janouschek H, Raptis M, Hellmann S, Veselinovic T, Bröcheler A, Boy C, Cumming P, Hiemke C, Rösch F, Schäfer WM, Gründer G.

Int J Neuropsychopharmacol. 2010 Aug;13(7):951-60. doi: 10.1017/S1461145710000374. Epub 2010 Apr 15.

PMID:
20392299
8.

Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.

Kegeles LS, Slifstein M, Xu X, Urban N, Thompson JL, Moadel T, Harkavy-Friedman JM, Gil R, Laruelle M, Abi-Dargham A.

Biol Psychiatry. 2010 Oct 1;68(7):634-41. doi: 10.1016/j.biopsych.2010.05.027. Epub 2010 Jul 31.

9.

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.

Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF.

Neuropsychopharmacology. 2002 Aug;27(2):248-59.

10.

D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia.

Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J.

Schizophr Res. 2006 Jul;85(1-3):232-44. Epub 2006 May 19.

PMID:
16713185
11.
12.

Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.

Takahata K, Ito H, Takano H, Arakawa R, Fujiwara H, Kimura Y, Kodaka F, Sasaki T, Nogami T, Suzuki M, Nagashima T, Shimada H, Kato M, Mimura M, Suhara T.

Psychopharmacology (Berl). 2012 Jul;222(1):165-72. doi: 10.1007/s00213-011-2633-5. Epub 2012 Jan 12.

PMID:
22237854
13.

Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride.

Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X, Yasillo N, Chen CT, Mintzer R, Cooper M.

Nucl Med Biol. 1999 Jul;26(5):519-27.

PMID:
10473190
14.

Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.

Tateno A, Arakawa R, Okumura M, Fukuta H, Honjo K, Ishihara K, Nakamura H, Kumita S, Okubo Y.

J Clin Psychopharmacol. 2013 Apr;33(2):162-9. doi: 10.1097/JCP.0b013e3182825bce.

PMID:
23422369
15.

[18F]Fallypride PET measurement of striatal and extrastriatal dopamine D 2/3 receptor availability in recently abstinent alcoholics.

Rominger A, Cumming P, Xiong G, Koller G, Böning G, Wulff M, Zwergal A, Förster S, Reilhac A, Munk O, Soyka M, Wängler B, Bartenstein P, la Fougère C, Pogarell O.

Addict Biol. 2012 Mar;17(2):490-503. doi: 10.1111/j.1369-1600.2011.00355.x. Epub 2011 Oct 3.

PMID:
22023291
16.

D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.

Potkin SG, Keator DB, Kesler-West ML, Nguyen DD, van Erp TG, Mukherjee J, Shah N, Preda A.

CNS Spectr. 2014 Apr;19(2):176-81. doi: 10.1017/S109285291300059X. Epub 2013 Sep 30.

PMID:
24073841
17.

Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study.

Suzuki T, Graff-Guerrero A, Uchida H, Remington G, Caravaggio F, Borlido C, Pollock B, Mulsant B, Deluca V, Ismail Z, Mamo D.

Psychopharmacology (Berl). 2013 Jul;228(1):43-51. doi: 10.1007/s00213-013-3012-1. Epub 2013 Feb 17.

18.

Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.

Arakawa R, Ito H, Takano A, Okumura M, Takahashi H, Takano H, Okubo Y, Suhara T.

Psychopharmacology (Berl). 2010 May;209(4):285-90. doi: 10.1007/s00213-010-1783-1. Epub 2010 Mar 27.

PMID:
20349050
19.

In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.

Slifstein M, Hwang DR, Huang Y, Guo N, Sudo Y, Narendran R, Talbot P, Laruelle M.

Psychopharmacology (Berl). 2004 Sep;175(3):274-86.

PMID:
15024551
20.

Decreased dopamine D2/D3-receptor binding in temporal lobe epilepsy: an [18F]fallypride PET study.

Werhahn KJ, Landvogt C, Klimpe S, Buchholz HG, Yakushev I, Siessmeier T, Müller-Forell W, Piel M, Rösch F, Glaser M, Schreckenberger M, Bartenstein P.

Epilepsia. 2006 Aug;47(8):1392-6.

PMID:
16922886
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk